| Type : |
Journal |
| Internet-link : |
https://ijpc.com/Abstracts/Abstract.cfm?ABS=4750 |
|
| Forskerhold : |
Sydney - National Institute of Complementary Medicine, Western Sydney University |
| Forfattere : |
Jarouche M, Ibrahim M, Pearson J, Venkataya B, Low M, Rowe J. |
| Titel : |
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets. |
| Nummer : |
Int J Pharm Compound ;24,1:77-82 2020 |
|
| Cotationvaleur : |
|
| Fysisk stabilitet : |
|
| Kemisk stabilitet : |
|
| Andre metoder : |
|
| Kommentarer : |
|
Lister
 Metronidazole
|
 |
 |
 |
 |
3000 mg
Metrogyl® |
|
25°C |
 |
| 90 |
 |
|
|
|
|
|
3000 mg
Metrogyl® |
|
25°C |
|
| 90 |
|
|
|
|
|
 |
3000 mg
® = ? |
|
25°C |
|
| 90 |
|
|
|
|
|
|
3000 mg
® = ? |
|
25°C |
|
| 90 |
|
|
|
|
|
|
3000 mg
Metrogyl® |
|
4°C |
|
| 90 |
|
|
|
|
|
|
3000 mg
Metrogyl® |
|
4°C |
|
| 90 |
|
|
|
|
|
|
3000 mg
® = ? |
|
4°C |
|
| 90 |
|
|
|
|
|
|
3000 mg
® = ? |
|
4°C |
|
| 90 |
|
|
|
|
 |
|
150 mg
Metrogyl® |
|
25°C |
|
| 90 |
|
|
|
|
|
|
150 mg
Metrogyl® |
|
25°C |
|
| 90 |
|
|
|
|
|
|
150 mg
® = ? |
|
25°C |
|
| 90 |
|
|
|
|
|
|
150 mg
Metrogyl® |
|
4°C |
|
| 90 |
|
|
|
|
|
|
150 mg
® = ? |
|
4°C |
|
| 90 |
|
|
|
|
|
|
150 mg
Metrogyl® |
|
4°C |
|
| 90 |
|
|
|
|
|
